Zobrazeno 1 - 10
of 62
pro vyhledávání: '"H. Narjes"'
Publikováno v:
British Journal of Clinical Pharmacology. 50:69-72
Aims Fibrinogen receptor antagonists show a close relationship between plasma concentrations and inhibitory effect. Optimal efficacy at an acceptable bleeding risk requires low inter- and intrasubject variability on low peak trough fluctuation in rec
Publikováno v:
Scopus-Elsevier
Using acetylsalicylic acid-dipyridamole, a combined thromboxane receptor antagonist-thromboxane synthase inhibitor, and a fibrinogen receptor antagonist as examples, this article discusses the predictive value of several methods that may be employed
Publikováno v:
Scopus-Elsevier
The pharmacokinetics of meloxicam were investigated in 12 patients with clinically stable liver cirrhosis after a single oral dose of 15mg. 12 healthy volunteers received the same regimen in earlier studies and the results of both groups were compare
Aims To characterize the pharmacokinetics of terbogrel, a new combined thromboxane A2 (TxA2) receptor and synthase inhibitor, in healthy human subjects after single or multiple oral administration. Methods Forty-eight healthy male subjects received a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::362bd351ccf567c2f49707198ad91f48
https://europepmc.org/articles/PMC1884538/
https://europepmc.org/articles/PMC1884538/
Publikováno v:
Scopus-Elsevier
The aims of the present evaluation were to determine whether the elevations in liver enzymes observed in phase-I trials are more common in subjects being hospitalised than in ambulatory subjects and to assess the relevance of these elevations. We the
Publikováno v:
British journal of clinical pharmacology. 50(1)
Fibrinogen receptor antagonists show a close relationship between plasma concentrations and inhibitory effect. Optimal efficacy at an acceptable bleeding risk requires low inter- and intrasubject variability on low peak trough fluctuation in receptor
Publikováno v:
Arzneimittel-Forschung. 47(3)
Meloxicam (CAS 71125-38-7, UH-AC 62 XX) is a new non-steroidal anti-inflammatory drug (NSAID) which was developed for the treatment of osteoarthritis and rheumatoid arthritis. The basic clinical pharmacokinetics of meloxicam (7.5-30 mg) have been inv
Publikováno v:
Scopus-Elsevier
1. The pharmacokinetics and tolerability of a new nonsteroidal anti-inflammatory drug (NSAID), meloxicam, administered i.m., were investigated in two studies conducted in healthy male volunteers. Study 1 was an open, placebo-controlled design in whic
Publikováno v:
European journal of clinical pharmacology. 51(3-4)
Objective: The pharmacokinetics of meloxicam have been studied following administration of a single 15-mg capsule to 12 patients with end-stage renal failure. Pharmacokinetic parameters were determined after haemodialysis. The pharmacokinetic profile
The influence of multiple-dose administration of meloxicam on the pharmacokinetics of oral beta-acetyl-digoxin was studied in 12 healthy male volunteers in a randomized double-blind two-way crossover study. The primary endpoint, Cminss, was within th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::caf0fb703188d4c1bacc18d5137e8f87
https://europepmc.org/articles/PMC1365196/
https://europepmc.org/articles/PMC1365196/